Archived explainer. For the current picture see today's LEGN page.
LEGEND BIOTECH CORP ADR (LEGN) is down -13.28% in the latest session. Our newswire has captured 11 stories on LEGN across 8 sources in the last 36 hours, with AI sentiment reading mixed (avg 45/100).
Legend Biotech Corp ADR (LEGN) fell 13.28% to $19.27 in the latest session, marking a sharp decline driven by the unexpected departure of CEO Ying Huang. The stock has been under pressure following the announcement that Huang stepped down as CEO and board member effective July 24. The leadership change has raised concerns among investors, especially as Huang had been a key figure in steering the company’s development pipeline and long-term strategy.
The company announced that Ying Huang, Ph.D., has stepped down as chief executive officer and board member. Alan Bash has been appointed as interim CEO. While Huang stated he is pursuing an opportunity at an early-stage venture company, he expressed confidence in Legend Biotech’s strategy and long-term growth during a sell-side call. The board emphasized continuity and stability in its messaging, highlighting the company’s commitment to advancing its cell therapy pipeline. However, the sudden change in leadership has triggered a sell-off, with analysts from Raymond James and RBC lowering price targets in response to the CEO transition.
Over the last eight sessions, LEGN has fallen 15.7% from $22.71 to $19.15. The stock currently trades within its 52-week range of $16.24 to $44.78. Recent insider transactions include two sales totaling $171,000, with the most recent filing on July 2. The stock has a market cap of $4.3 billion and remains unprofitable, with a trailing twelve-month net margin of -22.0%. Despite a 56.4% revenue increase year to date, the company’s earnings per share remain negative at -1.38.
The stock is set to remain in focus as analysts continue to reassess the company’s trajectory under new leadership. Investors should monitor upcoming analyst coverage and any updates on the company’s pipeline developments.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Not financial advice.
Legend said on Monday that Ying Huang stepped down as chief executive officer and board member effective July 24.
Huang said he will be pursuing an opportunity at an early-stage venture company, but remains confident in Legend's strategy, pipeline and long-term growth opportunities during a sell-side call, Morgan Stanley analysts said in a note.
Legend Biotech has announced a CEO change, appointing Alan Bash as interim CEO after Ying Huang, Ph.D., steps down. The company, a leader in cell therapy, emphasizes stability and continuity amid the leadership shift, while confirming ongoing commitment to its growth strategy and innovation in CAR-T therapies.
Raymond James cuts Legend Biotech stock price target on CEO departure
RBC cuts Legend Biotech stock price target to $59 on model updates
Why is Legend Biotech stock sliding today?
Legend Biotech stock falls as CEO Ying Huang steps down
Legend Biotech announces a change in leadership as Ying Huang, Ph.D., steps down as CEO, with Alan Bash appointed Interim CEO. The company underscores stability and a commitment to advancing its pioneering cell therapies amid the executive transition. Here’s what the leadership change means for the future of Legend Biotech and its pipeline.
More on LEGN: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier LEGN move explainers: 2026-07-28 · 2026-07-27